Tissue factor pathway inhibitor for cardiovascular disorders

Bibliography

• BROZE GJ, JR.: Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag. Fibrinol. (1995) 6 (Suppl. 1):S7–S13.
   PubMedGoogle Scholar
• BROZE GJ, JR.: Tissue factor pathway inhibitor and the revised theory of coagulation. Ann. Rev. Med. (1995) 46:103–112.
   PubMed Web of Science ®Google Scholar
• MANN KG, KALAFATIS M: The coagulation explosion. Cerebrovasc. Dis. (1995) 5:93–97.
   Web of Science ®Google Scholar
• CAMERER E, KOLSTO AB, PRYDZ H: Cell biology of tissue factor, the principal initiator of blood coagula-tion. Thromb. Res. (1996) 81 (0 :1–41.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review on tissue factor.
   Google Scholar
• BROZE GJ, JR., GIRARD TJ, NOVOTNY WF: Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry (1990) 29(33):7539–7546.
   PubMed Web of Science ®Google Scholar
• BROZE GJ, JR.: Tissue factor pathway inhibitor. Thromb. Haemost. (1995) 74(1):90–93.
   PubMed Web of Science ®Google Scholar
• ••Primary reference article on structure, chemistry andfunction of TFPI.
   Google Scholar
• GIRARD TJ, WARREN LA, NOVOTNY WF, et al: Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature (1989) 338(6215):518–520.
   PubMed Web of Science ®Google Scholar
• GIRARD TJ, MCCOURT D, NOVOTNY WG: Endogenous phosphorylation of the lipoprotein-associated coagulation inhibitor at serine-2. Biochem. J. (1990) 270 (3):621–625.
   PubMed Web of Science ®Google Scholar
• BROZE GJ, JR., WARREN LA, NOVOTNY et al. Thelipoprotein-associated coagulation inhibitor that inhibits the Factor WI-tissue factor complex also inhibits Factor Xa: insights into its possible mechanism of action. Blood (1988) 71(2) 335–343
   PubMed Web of Science ®Google Scholar
• HUANG ZF, WUN TC, BROZE GJ, JR.: Kinetics of FactorXa inhibition by tissue factor pathway inhibitor. J. Biol. Chem. (1993) 286(36):26950–26955.
   Google Scholar
• LINDHOUT T, FRANSSEN J, WILLEMS G: Kinetics of theinhibition of tissue factor-Factor Vila by tissue factor pathway inhibitor. Thromb. Haemost. (1 9 9 5) 74 (3):910–915.
   PubMed Web of Science ®Google Scholar
• RAPAPORT SI: Inhibition of Factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a Factor Xa-dependent inhibitory mechanism. Blood (1989) 73(2):359–365.
   PubMed Web of Science ®Google Scholar
• RAPAPORT SI: The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagula-tion. Thromb. Haemost. (1991) 66(0:6–15.
   PubMedGoogle Scholar
• YONEDA T, KOMOOKA H, UMEYAMA H: A computer modeling study of the interaction between tissue factor pathway inhibitor and blood coagulation Factor Xa. J. Protein Chem. (1997) 16(6):597–605.
   PubMedGoogle Scholar
• BAUGH RJ, BROZE GJ, JR., KRISHNASWAMY S: Regula-tion of extrinsic pathway Factor Xa formation by tissue factor pathway inhibitor. J. Biol. Chem. (1998) 273(8)4378–4386.
   PubMed Web of Science ®Google Scholar
• PETERSEN LC, BJORN SE, OLSEN OH, et al.: Inhibitory properties of separate recombinant Kunitz-type-protease inhibitor domains from tissue-factor-pathway inhibitor. Eur. J. Biochem. (1 9 9 6) 235(1–2)310–316.
   Google Scholar
• LINDHOUT T, WILLEMS G, BLEZER R, HEMKER HC: Kinetics of the inhibition of human Factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor. Biochem. J. (1994) 297 (Pt 1) :131–136.
   PubMedGoogle Scholar
• VALENTIN S, REUTLINGSPERGER CP, NORDFANG 0, LINDHOUT T: Inhibition of Factor Xa activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive Factor VIIa. Thromb. Haemost. (1995) 74(6):1478–1485.
   PubMed Web of Science ®Google Scholar
• PETERSEN LC, VALENTIN S, HEDNER U: Regulation of the extrinsic pathway system in health and disease: the role of Factor VIIa and tissue factor pathway inhibitor. Thromb. Res. (1995) 79(1):1–47.
   Google Scholar
• ••Excellent review on the TF-mediated coagulation pathwayand the role of TFPI
   Google Scholar
• VALENTIN S, NORDFANG 0, BREGENGARD C, WILDGOOSE P: Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coag. Fibrinol (1993) 4(5):713–720.
   PubMed Web of Science ®Google Scholar
• HOLST J, LINDBLAD B, BERGQVIST D, et al.: Antithrom-botic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis model. Haemostasis (1993) 23 (Suppl. 0:112–117.
   PubMedGoogle Scholar
• IINO M, FOSTER DC, KISIEL W: Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler. Thromb. Vasc. Biol. (1998) 18(0:40–46.
   PubMedGoogle Scholar
• PETERSEN LC, SPRECHER CA, FOSTER DC, et al.: Inhibi-tory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry (1996) 35(1) :266–272.
   PubMed Web of Science ®Google Scholar
• NOVOTNY WF, GIRARD TJ, MILETICH JP, BROZE GJ, JR.: Purification and characterization of lipoprotein associated coagulation inhibitor from human plasma. J. Biol. Chem. (1989) 264(30:18832–18837.
   PubMed Web of Science ®Google Scholar
• BROZE GJ, JR., LANGE GW, DUFFIN KL, MACPHAIL L:Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coag. Fibrinol. (1994) 5(4)551–559.
   PubMed Web of Science ®Google Scholar
• NOVOTNY WF, GIRARD TG, MILETICH JP, BROZE GJ, JR.: Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood (1988) 72(6)2020–2025.
   PubMed Web of Science ®Google Scholar
• PALMIER MO, HALL LJ, REISCH CM, et al.: Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb. Haemost. (1992) 68(0:33–36.
   PubMedGoogle Scholar
• BREGENGAARD C, NORDFANG 0, OSTERGAARD P, et al.Pharmacokinetics of full-length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb. Haemost. (1 9 9 3) 70(3)454–457.
   PubMedGoogle Scholar
• ELSAYED YA, NAKAGAWA K, KAMIKUBO YI, et al.: Effectsof recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distri-bution in a rat DIC model. Am. J. Clin. Pathol. (1996) 106(5)574–583.
   Google Scholar
• KAMIKUBO Y, HAMURO T, MATSUDA J, et al.: Antithrom-botic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravas-cular coagulation in rats: concerted effect with antithrombin. Thromb. Haemost. (1996) 76(4)621–626.
   PubMed Web of Science ®Google Scholar
• KAMIKUBO Y, HAMURO T, MATSUDA J, et al.: The clearance of proteoglycan-associated human recombi-nant tissue factor pathway inhibitor (h-rTFP0 in rabbits: a complex formation of h-rTFPI with Factor Xa promotes a clearance rate of h-rTFPI. Thromb. Res. (1996) 83(2):161–173.
   PubMed Web of Science ®Google Scholar
• NARITA M, BUG, OLINS GM, et al.: Two receptor systemsare involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J. Biol. Chem. (1995) 270(42)24800–24804.
   PubMed Web of Science ®Google Scholar
• KAISER B, HOPPENSTEADT DA, FAREED J: RecombinantTFPI and variants: potential implications in the treatment of cardiovascular disorders. Exp. Opin. Invest. Drugs (1998) 7(7):1121–1137.
   PubMedGoogle Scholar
• MANN KG, VAN'T VEER C, CAWTHERN K, BUTENAS S: The role of the tissue factor pathway in initiation of coagulation. Blood Coag. Fibrinol (1998) 9\(Suppl. 1):S3–S7.
   PubMedGoogle Scholar
• HOPPENSTEADT DA: Tissue factor pathway inhibitor as a modulator of post surgical thrombogenesis. Experi-mental and clinical studies. Thesis for the degree of Doctor of Philosophy, University of London, UK (1996).
   Google Scholar
• •Good survey of experimental and especially clinical studies on TFPI.
   Google Scholar
• TAUBMAN MB, FALLON JT, SCHECTER AD, et al.: Tissue factor in the pathogenesis of atherosclerosis. Thromb. Haemost. (1997) 78 (1) :200–204.
   PubMed Web of Science ®Google Scholar
• OSTERUD B: Tissue factor: a complex biological role. Thromb. Haemost. (1997) 78(1)755–758.
   PubMedGoogle Scholar
• SATO Y, ASADA Y, MARUTSUK AK, et al Tissue factorpathway inhibitor inhibits aortic smooth muscle cellmigration induced by tissue factor/Factor Vila complex. Thromb. Haemost. (1997) 78 (3):1138–1141.
   PubMed Web of Science ®Google Scholar
• KAMIKUBO Y, NAKAHARA Y, TAKEMOTO S, et al.: Humanrecombinant tissue factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett. (1997) 407(1):116–120.
   PubMed Web of Science ®Google Scholar
• HAMURO T, KAMIKUBO Y, NAKAHARA Y, MIYAMOTO S, FUNATSU A: Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells. FEBS Lett. (1 9 9 8) 421(3):197–202.
   PubMed Web of Science ®Google Scholar
• JANG Y, GUZMAN LA, LINCOFF AM, et al: Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation (1995) 92(10)3041–3050.
   PubMedGoogle Scholar
• OLTRONA L, SPEIDEL CM, RECCHIA D, et al.: Inhibition of tissue factor-mediated coagulation markedly attenu-ates stenosis after balloon-induced arterial injury in minipigs. Circulation (1997) 96(2):646–652.
   PubMed Web of Science ®Google Scholar
• ST PIERRE J, YANG LY, TAMIRISA K, et al: Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler. Thromb. Vasc. Biol. (1999) 19(9):2263–2268.
   PubMed Web of Science ®Google Scholar
• ASADA Y, HARA S, TSUNEYOSHI A, et al.: Fibrin-rich and platelet-rich thrombus formation on neointima: recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta. Thromb. Haemost. (1998) 80(3):506–511.
   PubMed Web of Science ®Google Scholar
• HAN X, GIRARD TJ, BAUM P, ABENDSCHEIN DR, BROZE GJ, JR.: Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat. Arterioscler. Thromb. Vasc. Biol. (1999) 19(102563–2567.
   Google Scholar
• YUTANI C, IMAKITA M, ISHIBASHI-UEDA H, et al.:Coronary atherosclerosis and interventions: pathological sequences and restenosis. Pathol InL (1999) 49(4):273–290.
   PubMed Web of Science ®Google Scholar
• FERRARIO M, MERLINI PA, LUCREZIOTTI S, et al.: Antithrombotic therapy of unstable angina and non-Q-wave myocardial infarction. Int. J. Cardiol. (1999) 68\(Suppl. 1):S63–571.
   PubMed Web of Science ®Google Scholar
• ASADA Y, MARUTSUKA K, HATAKEYAMA K, et al.: The role of tissue factor in the pathogenesis of thrombosis and atherosclerosis. J. Atheroscler. Thromb. (1998) 4(3):135–139.
   PubMedGoogle Scholar
• FALCIANI M, GORI AM, FEDI S, et al.: Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb. Haemost. (1998) 79(3):495–499.
   PubMed Web of Science ®Google Scholar
• SOEJIMA H, OGAWA H, YASUE H, et al.: Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation (1999) 99 (22):2908–2913.
   PubMed Web of Science ®Google Scholar
• KAMIKURA Y, WADA H, YAMADA A, et al. Increasedtissue factor pathway inhibitor in patients with acute myocardial infarction. Am. J. Hematol. (1997) 55(4):183–187.
   PubMed Web of Science ®Google Scholar
• FREEBURN JC, WALLACE JM, STRAIN JJ, et al: Monocyte tissue factor-like activity in post myocardial infarction patients. Br. J. Haematol. (1998) 102(2)605–608.
   PubMedGoogle Scholar
• SAITO Y, WADA H, YAMAMURO M, et al: Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. Am. J. Hematol. (1999) 61(4):238–242.
   PubMed Web of Science ®Google Scholar
• ABUMIYA T, YAMAGUCHI T, TERASAKI T, et al.Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thromb. HaemosL (1995) 74(4):1050–1054.
   PubMed Web of Science ®Google Scholar
• DREW AF, DAVENPORT P, APOSTOLOPOULOS J, TIPPINGPG: Tissue factor pathway inhibitor expression in atherosclerosis. Lab. Invest. (1997) 77(4):291–298.
   PubMed Web of Science ®Google Scholar
• KAIKITA K, TAKEYA M, OGAWA H, et al. Co-localizationof tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J. Pathol. (1 9 9 9) 188(2):180–188.
   PubMed Web of Science ®Google Scholar
• CAPLICE NM, MUESKE CS, KLEPPE LS, SIMARI RD:Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation (1 9 9 8) 98(10:1051-1057.
   Google Scholar
• PETIT L, LESNIK P, DACHET C, MOREAU M, CHAPMAN MJ:Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages. Relationship to tissue factor induction by cholesterol and oxidized LDL. Arterioscler. Thromb. Vasc. Biol. (1999) 19(2):309–315.
   PubMed Web of Science ®Google Scholar
• ARIENS RA, ALBERIO G, MOIA M, MANNUCCI PM: Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb. HaemosL (1999) 81(2):203–207.
   PubMed Web of Science ®Google Scholar
• KLEESIEK K, SCHMIDT M, GOTTING C, et al.: The 536C->T transition in the human tissue factor pathway inhibitor (TFP0 gene is statistically associated with a higher risk for venous thrombosis. Thromb. HaemosL (1999) 82(1):1–5.
   PubMed Web of Science ®Google Scholar
• SHIMURA M, WADA H, WAKITA Y, et al. Plasma tissuefactor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am. J. Hematol. (1997) 55(4):169–174.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI H, SATO N, SHIBATA A: Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: comparison of its behavior with plasma tissue factor. Thromb. Res. (1995) 80(4)339–348.
   PubMed Web of Science ®Google Scholar
• YAMAMURO M, WADA H, KUMEDA K, et al.: Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation. Blood Coagul. Fibrinolysis (19 9 8) 9(6):491–497.
   PubMed Web of Science ®Google Scholar
• SHIMURA M, WADA H, NAKASAKI T, et al. Increasedtruncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am. J. Hematol (1999) 60(2)94–98.
   PubMedGoogle Scholar
• VELASCO F, LOPEZ-PEDRERA C, BORRELL M, FONTCU-BERTA J, TORRES A: Elevated levels of tissue factor pathway inhibitor in acute non-lymphoblastic leukemia patients with disseminated intravascular coagulation. Blood Coag. Fibrinol. (1997) 8(1)70–72.
   PubMed Web of Science ®Google Scholar
• MATSUO T, KOIDE M, KARIO K, SUZUKI S, MATSUO M: Extrinsic coagulation factors and tissue factor pathway inhibitor in end-stage chronic renal failure. Haemostasis (1997) 27(4):163–167.
   PubMedGoogle Scholar
• YORIOKA N, TANIGUCHI Y, YAMASHITA K, et al.: Tissue factor and tissue factor pathway inhibitor in hemodialysis patients. Int. J. Anil Organs (1998) 21 (11):699–701.
   PubMed Web of Science ®Google Scholar
• LUZZATTO G, BERTOLI M; CELLA G, et al.: Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb. Res. (1998) 89(3):115–122.
   PubMed Web of Science ®Google Scholar
• ARIENS RAS, MOIA M, RIVOLTA E; PONTICELLI C, MANNUCCI PM: High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria. Thromb. HaemosL (1999) 82 (3):1020–1023.
   PubMed Web of Science ®Google Scholar
• MATSUDA T, MORISHITA E, JOKAJI H, et al.: Mechanism on disorders of coagulation and fibrinolysis in diabetes. Diabetes (1996) 45 (Suppl. 3):S109–S110.
   PubMedGoogle Scholar
• LEURS PB, VAN OERLE R, WOLFFENBUTTEL BH, HAMULYAK K: Increased tissue factor pathway inhibitor (TFP0 and coagulation in patients with insulin-dependent diabetes mellitus. Thromb. HaemosL (1997) 77(3):472–476.
   PubMed Web of Science ®Google Scholar
• HUVERS FC, DE LEEUW PW, HOUBEN AJ, et al.: Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in Type 1 diabetes under near-normoglycemic conditions. Diabetes (1999) 48 (6):1300–1307.
   PubMed Web of Science ®Google Scholar
• IVERSEN N, LINDAHL AK, ABILDGAARD U: Elevated TFPIin malignant disease: relation to cancer type and hypercoagulation. Br. J. Haematol. (1 9 9 8) 102(4)889–895.
   PubMedGoogle Scholar
• NOVOTNY WF, PALMIER M, WUN TC, BROZE GJ, JR., MILETICH JP: Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood (1991) 78 (2):394–400.
   PubMed Web of Science ®Google Scholar
• OSTERGAARD P, NORDFANG 0, PETERSEN LC, VALENTIN S, KRISTENSEN H: Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins Haemostasis (1993) 23 (Suppl. 1):107–111.
   PubMedGoogle Scholar
• COHEN M, DEMERS C, GURFINKEL EP, et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl. J. Med. (1997) 337(7):447–452.
   PubMed Web of Science ®Google Scholar
• SOEJIMA H, OGAWA H, YASUE H, et al.: Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris. Thromb. Res. (1999) 93 (1):17–25.
   PubMed Web of Science ®Google Scholar
• GORI AM, PEPE G, ATTANASIO M, et al. Tissue factorreduction and tissue factor pathway inhibitor release after heparin administration. Thromb. Haemost. (1999) 81(4):589–593.
   PubMed Web of Science ®Google Scholar
• BECKER RC, SPENCER FA, LI Y et al.: Thrombin genera-tion after the abrupt cessation of intravenous unfrac-tionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential. J. Am. Coll. Cardiol. (1999) 34(4):1020–1027.
   PubMed Web of Science ®Google Scholar
• LUPU C, POULSEN E, ROQUEFEUIL S, et al.: Cellulareffects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler. Thromb. Vasc. Biol. (1999) 19(9):2251–2262.
   PubMed Web of Science ®Google Scholar
• HANSEN JB, SANDSET PM, HUSEBY KR, et al: Differentialeffect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br. J. Haematol (1998) 1O1(4):638–646.
   Google Scholar
• FAREED J, HOPPENSTEADT D, BICK RL: New antithrom-botic drugs: a perspective. Curr. Opin. Cardiovasc. Pulm. Renal Invest. Drugs (1999) 1(1):40–55.
   Google Scholar
• FAREED J, LEWIS BE, CALLAS DD, et al: Antithrombinagents: the new class of anticoagulant and antithrom-botic drugs. Clin. Appl. Thrombosis/Hemostasis (1999) 5 (Suppl. 1):545–S55.
   Google Scholar
• WALENGA JM, JESKE W, HOPPENSTEADT D, KAISER B:Factor Xa inhibitors: today and beyond. Curr. Opin. Cardiovasc. Pulm. Renal Invest. Drugs (1999) 1(0:13–27.
   Google Scholar
• BAJAJ MS, BAJAJ SP: Tissue factor pathway inhibitor: potential therapeutic applications. Thromb. Haemost. (1997) 78(0:471–477.
   PubMed Web of Science ®Google Scholar
• •Thorough review on animal studies with TFPI and resulting potential clinical indications in humans.
   Google Scholar
• BROZE GJ, JR.: Tissue factor pathway inhibitor gene disruption. Blood Coag. Fibrinol. (1998) 9\(Suppl. 1):S89–S92.
   PubMedGoogle Scholar